Juanita Perkins
Family · Durham, NCNPI 1225163744
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $153,290 of the $213,377 with a category attached, or 71.8%. Johnson & Johnson accounts for 90.8% of it on its own, with 5 other manufacturers making up the rest. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $622.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$194K
- E.r. Squibb & Sons, L.L.C.$19K
- Otsuka America Pharmaceutical, Inc.$388
- Phathom Pharmaceuticals, Inc.$125
- Teva Pharmaceuticals USA, Inc.$122
- Otsuka Pharmaceutical Development & Commercialization, Inc.$25
What the payments were for
- Consulting fees$12,8406%
- Speaking & faculty fees$153,29072%
- Travel & lodging$39,50119%
- Food & beverage$7,6204%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 290 | $193,663 |
| E.r. Squibb & Sons, L.L.C. | 39 | $19,055 |
| Otsuka America Pharmaceutical, Inc. | 11 | $388 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$189,381
- INVEGA TRINZA$187,801
- COBENFY$11,083
- SPRAVATO$365
- REXULTI$232
- VOQUEZNA$125
- UZEDY$122
How this compares
$213,377 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 16 | $25,537 |
| Oxycodone Hcl | 72 | $1,794 |
| Buprenorphine Hcl | 13 | $1,400 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $1,357 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $637 |
| Pregabalin | 22 | $593 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $342 |
| Zolpidem Tartrate | 24 | $226 |
| Duloxetine Hcl | 16 | $199 |
| Diazepam | 20 | $177 |
| Paroxetine Hcl | 11 | $110 |
| Alprazolam | 23 | $102 |
| Lithium Carbonate | 12 | $86 |
| Quetiapine Fumarate | 17 | $72 |
| Sumatriptan Succinate | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $388 | $25,53716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Durham
- Nicole RothmanDurham$268K
- Melissa LamirandDurham$68K
- Amanda RidenhourDurham$13K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Teresa DossWilmington$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.